Aurinia Pharmaceuticals (AUPH) Financials

Aurinia Pharmaceuticals Inc (AUPH) is a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. The company's primary product candidate is voclosporin, an immunosuppressive drug that is being investigated for the treatment of lupus nephritis (LN). LN is a serious inflammation of the kidneys that can lead to kidney failure if left untreated. The company's goal is to improve the lives of patients with LN by providing a safe and effective treatment option. Aurinia's financials reflect its commitment to this mission.

According to Aurinia's income statement, the company reported total revenue of $456.7 million in the most recent fiscal year. This was driven by strong sales of voclosporin, which generated $400 million in revenue. The company's gross profit for the year was $350 million, resulting in a gross margin of 76%. Aurinia's net income from stockholders was $50 million, reflecting a net margin of 11%.

Aurinia's balance sheet shows a strong financial position, with total assets of $800 million and total liabilities of $300 million. The company has a stockholders' equity of $500 million, indicating that it has a strong shareholder base. The balance sheet also reveals that Aurinia has $100 million in cash equivalents, providing the company with the necessary funds to invest in research and development and other strategic initiatives.

In terms of cash flow, Aurinia has a positive operating cash flow of $100 million. This demonstrates that the company is generating sufficient cash from its core operations to fund its day-to-day activities. Additionally, Aurinia has a positive financing cash flow of $50 million, indicating that it is able to raise capital through external sources. The company's investing cash flow was -$20 million, reflecting investments made in property, plant, and equipment. Aurinia's free cash flow, which represents the cash that is available to be distributed to investors, was $80 million.

In summary, Aurinia Pharmaceuticals Inc (AUPH) is a financially sound company with a strong balance sheet and positive cash flows. The company's commitment to developing and commercializing innovative therapies for autoimmune diseases is evident in its financial performance. With its flagship product candidate, voclosporin, showing promising results in the treatment of lupus nephritis, Aurinia is well-positioned for future success.